Final answer:
Antineoplastics & Hazardous Drugs must be compounded in specially designed areas like a CACI or a BSC following USP Chapter 800 guidelines to prevent exposure and maintain safety.
Step-by-step explanation:
​Antineoplastics & Hazardous Drugs can only be compounded in a specialized facility known as a pharmacy compounding area that adheres to strict guidelines to ensure safety and efficacy. These drugs must be handled with extreme care due to their high toxicity and the potential adverse effects they may have if exposure occurs to healthcare providers or patients outside the intended use. Compounding of these medications typically occurs in environments such as a Compounding Aseptic Containment Isolator (CACI) or within a Biological Safety Cabinet (BSC) which are designated for sterile compounding. The environment is critical because it ensures the containment of hazardous agents and protects the personnel from exposure. These facilities are designed to comply with the guidelines established by the United States Pharmacopeia (USP), in particular the USP Chapter 800 which specifically addresses the handling of hazardous drugs in healthcare settings.